Search
for

    Glossary Bortezomib

    inhibits proteasomes to treat multiple myeloma and lymphoma

    Bortezomib, also known by the brand name Velcade, is a medication used primarily to treat multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasomes, which are enzyme complexes that break down proteins in cells, thereby causing cancer cells to die. This targeted action helps to control the growth and spread of cancerous cells.

    Research 10 of 76

    1. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects Cutaneous and Ocular Toxicology · 2013 · 18 citations
    2. 440 Topical application of anti-cancer drug Bortezomib stimulates proliferation of follicular cells and induces expression of hair keratins via GATA-3 transcription factor 2016
    3. 증례 : 몸통의 다발성 판으로 나타난 Bortezomib에 의한 약물 발진 2예 대한피부과학회지 · 2016
    4. Proteasome Inhibitors: An Expanding Army Attacking a Unique Target Chemistry & biology · 2012 · 474 citations
    5. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer Journal of the American Academy of Dermatology · 2014 · 88 citations
    6. Alopecia in patients treated with molecularly targeted anticancer therapies Annals of Oncology · 2015 · 44 citations
    7. Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis Eye · 2025 · 1 citations
    8. Cutis Verticis Gyrata Heralding a Diagnosis of Primary Systemic Amyloidosis in a Patient with Cardioembolic Stroke Annals of Indian Academy of Neurology · 2023 · 1 citations
    9. Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana Projeto: revista mensal de arquitetura · 2008
    10. Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database Scientific Reports · 2021 · 1 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →